News >

Venetoclax Demonstrates Strong Activity in CLL After BCR Inhibitor

Jason Harris
Published: Thursday, Jan 04, 2018

John Byrd, MD
John Byrd, MD
Patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who failed on previous treatment with a BCR signaling pathway inhibitor had an overall response rate of 65% following treatment with venetoclax (Venclexta).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x